Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its practical approach” to drug development, the analyst tells investors in a research note. The firm says the company has “potential best-in-class assets in high value therapeutic spaces” and a business approach focused on early stage value creation and monetization. Absci entered 2025 with several ongoing early stage and clinical programs, adds Needham.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI: